CHRONIC MYELOID LEUKEMIA

This study tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor in 21 people with various blood cancers like leukemia and lymphoma. The goal was to see if this approach could help patients survive and recover without severe side effects.…

This study tests whether combining two drugs, azacitidine and venetoclax, can help people with a higher-risk form of chronic myelomonocytic leukemia (CMML). About 44 adults with this rare blood cancer will receive the drug combination to see if it shrinks or controls the disease.…

This early-phase study tests whether giving healthy donor natural killer (NK) cells along with two drugs (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach/esophageal, or blood cancers. The NK cells are meant to attack cance…

This study looks at whether reducing the dose of the drug olverembatinib can still control chronic myeloid leukemia (CML) in patients whose cancer has already responded well to treatment. About 100 adults with CML in chronic or accelerated phase will take a lower dose (20 mg ever…

This study looks at whether people with chronic myeloid leukemia (CML) who have had a very low level of cancer for at least two years can safely stop taking their daily targeted therapy (TKI). Seventeen adults who have been on TKI for over three years will stop their medication a…

This study tests a stem cell transplant method that filters out certain immune cells (TCRαβ+ and CD19+) from a half-matched family donor's blood. The goal is to lower the risk of graft-versus-host disease, a serious complication, and allow patients to avoid long-term immune-suppr…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease. About 313 adults with various blood cancers…

This study looks at whether the drug nilotinib can help people with chronic myeloid leukemia (CML) stay in remission after stopping their usual treatment for a second or third time. It involves 75 adults who have already tried and failed to stop treatment before. Participants tak…

This study tests whether slowly reducing the dose of tyrosine kinase inhibitor (TKI) medication over 12 months helps more chronic myeloid leukemia (CML) patients stop treatment entirely without the cancer returning. About 170 adults with stable CML will be randomly assigned to ei…

This study follows 201 adults with chronic myeloid leukemia who are taking the drug Scemblix (asciminib) as a third or later treatment option. The goal is to see how long patients stay on the drug and how well it works in everyday medical practice, not just in controlled trials. …

This study looks at how blood cancers and stem cell transplants affect muscle function in 144 patients. Researchers want to see if muscle health can help predict complications like infections, relapse, or survival. The goal is to better understand the role of muscle strength at k…